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Abstract: Enhancing or prolonging T-cell activation by monoclonal antibodies (mAbs) blocking 
negative signaling receptors such as CTLA4 is one approach to overcoming tumor-induced 
immune tolerance. Ipilimumab and tremelimumab inhibit CTLA4, prolonging antitumor 
immune responses and leading to durable anti-tumor effects. Treatment with these mAbs has 
demonstrated clinically important and durable tumor responses and disease control rates in 
patients with unresectable advanced melanoma. Durable objective responses have been reported 
across a spectrum of doses and schedules, with relative safety in this patient population. Although 
the phase III tremelimumab melanoma study was closed for “futility”, the 1-year survival rate 
of  50% for tremelimumab and the median survival of 11.7 months (compared with 10.7 months 
for chemotherapy) are notable. Results of the phase III studies testing CTLA4-blockade with 
ipilimumab are eagerly anticipated. The further development of these agents includes testing in 
the neoadjuvant melanoma setting (ipilimumab) as well the adjuvant high-risk melanoma setting 
(ipilimumab). Future progress with CTLA-4 blockade therapy will also likely come from the use 
of combinations of agents that target several critical regulatory pathways of the immune system 
and modulate the immune response in the host in a synergistic and controlled fashion.
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Overcoming immune tolerance of tumor
New targets for overcoming tumor-induced immune tolerance have recently been 
identified resulting from an increasing understanding of several critical regulatory 
pathways of the immune system. Enhancing or prolonging T-cell activation by mono-
clonal antibodies (mAbs) blocking negative signaling receptors such as CTLA4 is one 
approach.1 Another strategy involves mAbs that stimulate dendritic cell (DC) receptor 
CD40 and oligodeoxynucleotides that activate DC toll-like receptor 9 (TLR9) to 
enhance the expression of costimulatory molecules on the surface of DCs.2–4 Such 
novel strategies are currently the targets of active clinical trial testing.5 This review 
will focus on the promise of CTLA4-blockade.
Cytotoxic T lymphocyte-associated antigen 4 
blockade
Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) is a key element in T-cell 
tolerance that serves as a natural braking mechanism for T-cell activation, allowing 
a return to homeostasis following an immune response. This was illustrated by early 
preclinical studies involving murine CTLA4 knockout models that were reported to OncoTargets and Therapy 2010:3 16
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develop a massive lymphoproliferative disorder, leading to 
lymphocytic infiltration and destruction of major organs.6–8 
CTLA4 also appears to be the main negative regulator of 
T-cell-mediated antitumor immune responses. Full T-cell 
activation requires engagement of the T-cell receptor to 
antigen-bound major histocompatibility complex (MHC) on 
the antigen-presenting cell as well as engagement of CD28 
on the T-cell surface by members of the B7 family (eg, B7.1/
CD80, B7.2/CD86, B7-H3, B7-H4) on the antigen-presenting 
cell.9 CTLA4 is a homologue of CD28 that functions as an 
inhibitory receptor for B7 costimulatory molecules expressed 
on mature antigen presenting cells.10–13 Following T-cell 
activation, CTLA4 cell-surface receptors, which have a higher 
binding affinity than CD28 for members of the B7 family, are 
upregulated and successfully compete with CD28 for binding 
to B7, sending an inhibitory signal that downregulates T-cell 
activation.12,14 Downstream targets of CTLA4 such as cytokine 
production by Th1 and Th2 cells15 and key components of the 
cell cycle machinery (Cdk-4, Cdk-6, and cyclin D3) required for 
cell cycle progression, are affected by this inhibitory signal.16–18 
This led to the hypothesis that blocking the CTLA4-B7 interac-
tion would lead to enhanced and prolonged T-cell activation, as 
measured by increased production of interleukin (IL)-2, IFN-γ, 
IL-3, IL-4, IL-5, and IL-10,10,15 and more clinically meaningful 
antitumor immune responses.
This approach has been examined in murine models 
wherein treatment with an anti-murine CTLA4 mAb 
enhanced T-cell immune function and T-cell mediated kill-
ing of various solid tumors, including fibrosarcoma, colon 
and prostate tumors.19–21 Anti-CTLA4 mAbs with a much 
greater affinity for CTLA4 than B7 that can bind CTLA4 
and block its interaction with B7 on the antigen-presenting 
cell (competitive inhibition) have been cloned.1 and have 
undergone extensive preclinical and clinical testing. This 
antitumor effect of CTLA-4 blockade appears to be due to 
increased T-cell activation rather than inhibition or depletion 
of  T regulatory cells.22
Tremelimumab
Tremelimumab (CP-675,206; Pfizer, Inc.) is a fully human 
IgG2 anti-CTLA4 mAb that has been developed for the 
treatment of patients with advanced cancer.23,24
Pharmacokinetics
Tremelimumab manifested a biphasic pharmacokinetic 
profile as observed in the first phase I clinical trial. This 
study treated 39 patients with a single intravenous infusion 
of tremelimumab (0.01 to 15 mg/kg).1,25 The maximum 
concentration (Cmax; range, 2 to 450 µg/mL) and area under 
the curve (AUC) increased in an approximately propor-
tional manner with dose.1,25 Most patients who experienced 
clinical benefit had a tremelimumab plasma concentration 
that was 30 µg/mL, the predicted clinical target based on 
preclinical studies, even 4 weeks post-dose. Clearance was 
low (mean = 0.132 mL/h/kg), and the steady-state volume of 
distribution was small (mean = 81.2 mL/kg).1,25 The terminal-
phase half-life of tremelimumab was 22.1 days, consistent 
with natural IgG2.1,26 In a subsequent multidose, phase I, 
dose-escalation study in 14 patients with metastatic mela-
noma, the 10 mg/kg dose maintained a therapeutic plasma 
level of tremelimumab.27 Tremelimumab is hypothesized 
to be cleared by endothelial cell uptake and proteolysis, the 
same processes responsible for clearance of natural, endog-
enous IgG2.28 A recent study investigated the relationship 
between pharmacokinetics (PK) and diarrhea or colitis in 
450 patients enrolled in 4 phase I or II clinical studies with 
tremelimumab. The severity of diarrhea and colitis appeared 
to be independent of PK, AUC90 (AUC during the first 
90 days), Cmax, C29 (concentration at day 29), and AUCG30 
(AUC of concentration 30 µg/mL) of tremelimumab. The 
frequency of diarrhea increased initially with increasing 
AUC, but reached a plateau quickly at approximately AUC 
value of 50,000 µg × h/mL (20th percentile). Results of the 
combined diarrhea and colitis analysis were similar to those 
of diarrhea alone.29
Clinical trials
Tremelimumab has been studied in clinical trials as a single 
agent and in combinations in patients with melanoma.1,30 
In addition, tremelimumab is being tested alone or in com-
bination therapy in patients with colorectal cancer,31 nons-
mall cell lung cancer (NSCLC),32 breast cancer,33 renal cell 
carcinoma,34 and prostate cancer.35,36
Phase I single-dose studies
A phase I, dose-escalation, single-dose study (A3671001) 
tested intravenously administered tremelimumab at doses 
ranging from 0.01 to 15 mg/kg. A total of 39 patients 
(melanoma = 34, renal cell carcinoma = 4, colon carci-
noma = 1) were treated, including 33 patients with measur-
able disease and 6 patients with either surgically resected or 
nonmeasurable disease.1,25 Five patients in the lowest dose 
cohorts (0.01 to 1 mg/kg) were re-enrolled at a higher dose 
level for a total of 44 administered doses. Three patients 
treated with 15 mg/kg experienced dose-limiting toxicities 
(DLTs) per protocol criteria that included grade 3 diarrhea OncoTargets and Therapy 2010:3 17
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and grade 3 rash. The maximum tolerated dose (MTD) was 
therefore defined at 10 mg/kg. The DLTs at 15 mg/kg were 
noted to be moderate in severity and resolved completely 
within 3 months of dosing.37
The objective response rate (RR) was 10% (2 complete 
remission (CR), 2 partial response (PR); all melanoma and 
all durable lasting 25 to 34 months) observed at the 3, 10, and 
15 mg/kg dosing levels.1,25 Four patients had stable disease 
(lasting 4 to 16 months). Five patients had prolonged periods 
without disease progression (23 to 36 months) after surgi-
cal resection of residual lesions.1,25
Phase I/II, II single-agent studies
The promising clinical activity in melanoma noted in the 
first single dose phase I study lead to a subsequent phase I/II 
multiple-dose, dose escalation study (A3671002) in inoper-
able advanced melanoma (N = 119).25,30 This study tested 
3, 6, or 10 mg/kg of tremelimumab administered monthly,27 
and the phase II recommended dose (P2D) was 10 mg/kg. 
At 10 mg/kg, one patient had a PR, and 5 other patients 
survived more than 14 months.27
By combining data from the initial phase I single-dose 
study (A3671001) and the phase I portion of the multiple 
dosing phase I/II study (A3671002), single and monthly 
dosing at 10 mg/kg were shown to be safe. A high rate of 
clinical benefit was observed at 15 mg/kg (A3671001) and 
the DLTs (grade 3 diarrhea and grade 3 rash) were noted 
to moderate and resolved completely within 3 months of 
dosing.30,37 Therefore, it was decided to proceed into the 
phase II portion of trial A3671002 comparing 10 mg/kg 
(monthly) with 15 mg/kg (every 3 months) dosing levels.25,30 
Among 89 patients treated (phase II), 7 (8%) had an objec-
tive response (3 CRs, 4 PRs; all durable ranging from 11 to 
34+ months), with similar clinical activity noted in both 
cohorts.30 In addition, 26 (29%) patients had stable disease. 
Median survival was reported at 10.2 and 11.5 months in 
the 10 mg/kg cohort (n = 44) and 15 mg/kg cohort (n = 45) 
groups, respectively.25,38 Moreover, there was a lower inci-
dence of grade 3 or 4 adverse events (AE) (13% compared 
with 27%)30 in the 15 mg/kg every 90 days dosing group 
and this was selected for further clinical testing.
A phase II expansion of this study evaluating 10 mg/kg 
given monthly, intravenously, in 14 melanoma patients, 
analyzed immune parameters in peripheral blood that may 
correlate with clinical responses. Evaluating circulating 
populations of MART-1-specific T-cells in patients who were 
positive for human leukocyte antigen (HLA)-A2.1,39 tremeli-
mumab was shown to reduce CD3 + CD4 + CD25 + Treg cells, 
decrease constitutive IL-10 production, and increase the ratio 
of IL-2/IL-10 production by anti-CD3 activated peripheral 
blood mononuclear cells (PBMCs) in patients with clinical 
benefit (response or stable disease).40
The 15 mg/kg every 90 days tremelimumab regimen 
(given intravenously [iv] peripheral blood up to 4 cycles, pro-
gression of disease, or intolerable toxicity) was further tested 
in a subsequent, second line, phase II study (A3671008) in 
inoperable, American Joint Committee on Cancer stage III 
or IV melanoma.41
The objective RR was 7% (16 PRs, all durable ranging 
from 91 to 540 + days. The 1-year survival rate was 41% 
with median survival of 10.1 months.41
A phase II study (N = 47) in heavily pretreated patients 
with metastatic colorectal cancer (A3671014),31,42 evaluated 
15 mg/kg intravenous tremelimumab every 3 months.31,42
One patient achieved a PR.42 All other patients had either 
disease progression or death as a result of their disease 
or discontinued therapy because of adverse events before 
reaching the planned second dose at 3 months. Of the 
49 patients treated, 18 survived 6 months or more.31,42
A randomized phase II clinical trial (A3671015) compared 
tremelimumab with best supportive care (BSC) following 
first-line platinum-based therapy in patients (N = 87) with 
advanced NSCLC.32 Ten (23%) patients receiving tremelim-
umab and 6 (14%) patients receiving BSC were progression 
free at 3 months. The progression-free survival (PFS) analysis 
did not demonstrate superiority of tremelimumab over BSC 
(H0: PFS at 3 months 50% was not rejected). However, 
the clinical activity (2 PRs) noted with tremelimumab 
may support future combination studies in NSCLC.32
Phase I and II studies of combination 
therapy with tremelimumab
A combination phase I dose escalation study studied treme-
limumab plus sunitinib in patients with metastatic renal 
cell carcinoma (mRCC).34 Among 21 patients enrolled, 
5 patients achieved a PR. Sunitinib at 37.5 mg daily and 
tremelimumab at 10 mg/kg every 12 weeks was considered 
the MTD.34
Tremelimumab in combination with dendritic cell vac-
cination has been evaluated in a dose-escalation phase I trial 
(investigator-initiated) in patients (N = 16) with metastatic 
melanoma.43 Tremelimumab was given at 3 to 10 mg/kg 
monthly or 10 to 15 mg/kg every 90 days in combination 
with a fixed dose of 1 × 107 MART-126–35 peptide-pulsed 
dendritic cells, given intradermally. Although the addition of 
MART-1 dendritic cells may have added to the overall toxicity OncoTargets and Therapy 2010:3 18
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of single-agent tremelimumab, this treatment combination 
had promising antitumor activity (25% objective response 
rate in which all responses were durable, including 1 CR 
and 3 PRs).43
A phase II, safety and efficacy combination biotherapy 
study is ongoing and evaluates tremelimumab administered 
concurrently with high-dose IFN-α2b in patients with inop-
erable stage III or IV melanoma.44 Patients in this study, 
which allows prior therapy, receive 15 mg/kg tremelimumab 
intravenously once every 90 days and concurrent IFN-α2b 
at 20 MU/m2 administered IV 5 days per week for 4 weeks 
followed by treatment with IFN-α2b at 10 MU/m2 adminis-
tered subcutaneously 3 days per week for 8 weeks. Interim 
analyses indicate that the frequency of grade 3 or 4 toxicities 
associated with this combination do not exceed those observed 
with the high-dose IFN regimen alone.44 Furthermore, of 
16 patients treated to date, promising antitumor activity has 
been observed: 3 patients had PR (19% objective response 
rate; lasting 4.0+, 7.0+, and 9.0 months) and 6 additional 
patients have achieved standard deviation (SD) (lasting 1.5 
to 8.0+ months).44 This study has proceeded to a second stage 
and is recruiting 21 additional patients. A significant associa-
tion between autoimmunity and clinical benefit was noted on 
this study. One out of seven patients with progressive disease 
versus eight out of nine patients with stable disease or PR 
had evidence of autoimmunity.
Preliminary results from a phase I dose escalation study 
of tremelimumab and PF-3512676, an oligodeoxynucleotide 
TLR 9 agonist, in advanced melanoma or other advanced 
cancers was recently reported. Among 15 patients treated 
to date (melanoma, n = 12; mesothelioma, n = 2; prostate, 
n = 1), 3 at dose level 1 (6 mg/kg tremelimumab + 0.05 mg/kg 
PF-3512676); 6 at dose level 2 (10 mg/kg tremelimumab + 
0.05 mg/kg PF-351276); and 6 at dose level 3 (15 mg/kg 
tremelimumab + 0.05 mg/kg PF-3512676), there were 
2 DLTs at dose level 3: G3 diarrhea (n = 1) and G3 nausea 
and vomiting associated with biopsy-proven duodenitis 
(n = 1). One DLT, G3 hypophysitis, occurred at dose 
level 2. Patients with DLTs responded to corticosteroid 
therapy. The MTD for this combination has yet to be deter-
mined, and a fourth intermediate dose level (10 mg/kg 
tremelimumab + 0.1 mg/kg PF-3512676) is currently being 
evaluated. Updated safety, efficacy, and PK data are also 
pending.45
A phase I, dose-escalation trial of tremelimumab com-
bined with exemestane in patients with advanced and hor-
mone receptor positive breast cancer enrolled 25 patients.33 
Overall, 65 cycles were administered, with patients receiving 
3 mg/kg tremelimumab every 28 days (n = 6), 6 mg/kg 
tremelimumab every 28 days (n = 1), 6 mg/kg tremelimumab 
every 90 days (n = 13), or 10 mg/kg every 90 days (n = 6). 
No PK interaction between tremelimumab and exemestane 
was reported. DLTs included transient elevation of serum 
transaminases in cycle 1 (grade 3 in 1 pt) and diarrhea in 
cycle 1 (grade 3 in 3 patientss, 1 of whom was hospitalized 
with steroid-refractory diarrhea and given anti-tumor necrosis 
factor-α mAb, infliximab) and cycle 2 (grade 3 in 1 patient). 
The MTD of tremelimumab in combination with exemestane 
on this study was estimated at 6 mg/kg every 90 days. There 
were no responses, but 8 patients had stable disease (lasting 
3 to 14 months).33
Phase III single-agent study
The promising clinical activity of tremelimumab in earlier 
trial testing in advanced melanoma has lead to a subse-
quent phase III clinical trial (A3671009) in patients with 
treatment naive advanced melanoma. This study random-
ized patients to therapy with single-agent tremelimumab 
(n = 328) or standard-of-care chemotherapy (n = 327) with 
either dacarbazine or temozolomid.46 Patients received either 
15 mg/kg tremelimumab iv (n = 324) every 3 months for up 
to 4 cycles or chemotherapy (n = 319) with either dacarbazine 
iv (1000 mg/m2) every 3 weeks for up to 12 cycles or oral 
temozolomide (200 mg/m2) on days 1 through 5 of every 
4 weeks for up to 12 cycles.46 The primary endpoint was over-
all survival (OS). At second interim analysis, the logrank 
test-statistic (P = 0.729) crossed the prespecified O’Brien–
Fleming futility boundary. The trial was halted for futility 
based on the recommendations of the Data Safety Monitor-
ing Board. Median survival in the tremelimumab arm was 
12.02 months and in the chemotherapy arm 10.45 months 
(hazard ratio chemotherapy/tremelimumab = 1.06; P = 0.587). 
The majority of responses to tremelimumab were durable. 
Additional follow up and assessment of data are ongoing to 
identify predictive factors of response that may broaden our 
understanding of clinical benefit observed in some patients.
Safety and tolerability of single-agent 
tremelimumab
Safety and tolerability of single-agent tremelimumab observed 
in 8 clinical trials in patients (N = 786) with advanced 
cancers (including melanoma, NSCLC, and colorectal 
cancer) have been analyzed retrospectively.47 The majority 
of patients (79%) treated with a median of 1 dose of treme-
limumab (range, 1 to 7) experienced at least 1 treatment-
related AE. However, these were mostly mild to moderate OncoTargets and Therapy 2010:3 19
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(grade 1 or 2). One hundred ninety patients (24%) developed 
AEs  grade 3. The most common AEs related to treatment 
were diarrhea (40%), rash (23%), and fatigue (23%).47 Endo-
crine effects on the thyroid, pituitary, or adrenal glands were 
associated with tremelimumab treatment, but the incidence 
did not exceed 5%. Treatment-related diarrhea occurred at 
a median of 23 days after treatment with tremelimumab.47 
Although ocular effects such as uveitis have been reported 
in patients treated with CTLA4 blockade,48,49 the incidence 
in this population did not exceed 5%.47 Overall, treat-
ment with tremelimumab was well tolerated in patients with 
advanced cancers.47
Ipilimumab
Ipilimumab (MDX-010; Medarex, Inc./Bristol-Myers Squibb 
Co.) is a fully humanized IgG1κ mAb against CTLA4.50
Pharmacokinetics
Specific attributes of ipilimumab were studied in a phase I 
trial in which a single dose of ipilimumab was given to 
patients suffering from advanced, refractory prostate carci-
noma. It was noted that the Cmax of the medication occurred 
at the completion of the ipilimumab infusion and that the 
mean Cmax was 155.94 ± 64.5 µg/mL. The mean terminal 
elimination half-life was comparable with human anti-
body half-life, lasting approximately 12.5 days. From this 
information it was seen that a single dose would maintain 
levels of over 10 µg/mL for at least 2 months (60 days). 
In another trial, a 3 mg/kg dose of ipilimumab was admin-
istered with a peptide vaccine to patients with metastatic 
melanoma every 3 weeks. After the first dose, the mean 
peak concentration was 72 ± 33 µg/mL and the trough 
level taken prior to the second dose was 12 ± 7 µg/mL. 
The mean plasma concentration after therapy was 99 ± 
41 µg/mL and a trough measured after 3 weeks of the last 
given treatment was 17 ± 10 µg/mL. No correlation was 
seen between the plasma concentrations and toxicity or 
antitumor activity.51 It was also seen that the concentra-
tion of ipilimumab increased with body weight and was 
unaffected by impaired hepatic or renal function or by use 
of steroids.52,53
Phase I single-dose studies
Two separate phase I studies were performed, both 
showing anti-tumor effects. The first trial was performed 
with 17 patients with progressive, unresectable melanoma, 
where a single infusion of ipilimumab was given at a rate of 
3 mg/kg over the span of 90 minutes.54 In the other phase I 
trial nine patients (seven with metastatic melanoma and two 
with ovarian cancer) were given a single dose of 3 mg/kg 
of ipilimumab. These patients had been previously vacci-
nated with either irradiated autologous GMCSF-secreting 
tumor cells or with autologous dendritic cells made to 
express gp100 peptide and IL-2 or with gp100 and MART-1 
peptides. After ipilimumab treatment, 3 patients with meta-
static melanoma experienced extensive tumor necrosis 
while 2 with metastatic ovarian cancer had a reduction or 
stabilization of their CA-125 levels. In this study, no serious 
toxicities were reported.55
Phase I, II single-agent studies
In a randomized phase I/II, dose escalation study of 
217 patients with unresectable stage III/IV melanoma were 
treated with ipilimumab (0.3, 3, 10 mg/kg every 3 weeks × 4). 
Maintenance dosing was done every 12 weeks and at week 
24 patients were assigned a blinded dose. Patients with PD 
could cross over to a 10 mg/kg dose. The objective response 
rate was 15.3%. Disease control rates (DCR: CR + PR + 
SD) at 0.3, 3, 10 mg/kg dose levels were 13.7%, 26.4% and 
29.2% respectively.56 It was seen that patients receiving 
10 mg/kg experienced a trend towards better survival (48.6% 
survival at 12 months and 34.5% at 18 months) and sub-
sequent studies were based on this dose recommendation. 
This was replicated in a study comparing the long-term 
survival in patients with advanced melanoma treated with 
ipilimumab alone or in combination with dacarbazine. 
A 2-year survival rate of 36% was seen in patients receiving 
10 mg/kg as compared to 22% in patients who had received 
3 mg/kg.57
A randomized phase II study was performed in patients 
with metastatic melanoma, where a combination of ipili-
mumab with dacarbazine was compared with ipilimumab 
alone. In the group only receiving ipilimumab, 2 underwent 
PR and 4 developed stable disease. In the combination group, 
2 attained CR and 4 had PR. Disease stabilization was seen 
in both groups with CR still present at 16 months and PR 
seen at 14 months.58
Other phase II studies were preformed in combination 
with other immunotherapy regimens. One study combined 
CTLA-4 inhibition with concomitant IL-2 administration, in 
an attempt to supplement the effect of IL-2 on tumor cells. 
Thirty-six patients were enrolled and received differing 
doses of the medication and overall the objective response 
rate to this combination was 22%. The conclusion drawn 
noted no synergistic effect, with no significant improve-
ment in response rate.49,51,59–61OncoTargets and Therapy 2010:3 20
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A phase II study of patients with unresectable stage III 
or stage IV melanoma tested ipilimumab at 10 mg/kg every 
3 weeks × 4 induction dosing in combination with placebo 
(Group A) or an oral steroid (budesonide) with minimal 
systemic exposure used to treat inflammatory bowel disease 
(Group B). For the 115 patients treated, there was no clini-
cally meaningful difference in the best overall response rate 
(BORR), DCR, or safety events. BORRs were 15.8% and 
12.1% and DCR were 35.1% and 31% in Groups A and B, 
respectively.62
Combinations of CTLA-4 antibodies with vaccines were 
also investigated, in attempts at overcoming tolerance. Pep-
tide vaccines have been used in the past in treatment regi-
mens for melanoma, where tumor-specific immunoreactivity 
was seen. It is of note that tumor regression was rarely seen 
unless IL-2 was given in combination. A majority of human 
tumor related antigens are nonmutated self-antigens. With 
this in mind, targeting immunity against these self-antigens 
would elaborate an appropriate response against these tumor 
cells. A study was performed on 56 patients with meta-
static melanoma where a combination of ipilimumab and 
a peptide vaccine was administered.49 Two different dose 
cohorts were examined; 27 patients were given 3 mg/kg 
of ipilimumab initially with a subsequent reduction to 1 
mg/kg every three weeks, while 29 patients 3 mg/kg dose 
every 3 weeks. No difference was seen on comparison of 
the response rates between these two groups. Grade III/IV 
toxicities were seen more in the later group (19% versus 
31%), though the overall rate of side effects between the 
two groups were not significant statistically. Twenty-five 
percent of the most significant side effects noted in this 
study were autoimmune in nature, including dermatitis, 
enterocolitis, hepatitis, colitis, hypophysitis and uveitis. 
It was also seen that in the 14 patients who had significant 
autoimmune toxicities, grade III or higher, 5 exhibited 
tumor regression. In comparison, only 2 patients in those 
who did not experience toxicities, in a total of 46, showed 
a tumor response.
A follow-up study to replicate this relationship between 
autoimmunity and tumor response was performed in an 
additional 46 patients who received both ipilimumab and 
a peptide vaccine. These patients were initially started at 
3 mg/kg or 5 mg/kg every 3 weeks, with subsequent doses 
escalated to a maximum of 9 mg/kg. Therapy was halted 
in patients who displayed noncutaneous adverse effects 
grade III or higher, or required the administration on ste-
roids for treatment for an autoimmune toxicity. Sixteen 
patients of these 46 developed grade III/IV autoimmune 
reactions at doses of 5 mg/kg or higher, with hypophysis 
being the most common. No correlation was noted between 
the increased incidence of grade III/IV effects and objective 
response rates.63
Potential prognostic factors were explored in a pooled 
analysis of two phase II studies where patients with meta-
static melanoma received 10 mg/kg dosing. Negative factors 
included male gender, aged over 60 years, baseline elevation 
of lactate dehydrogenase (LDH) levels and no response to 
prior therapy. It was seen that ipilimumab had clinical activity 
despite these negative factors and was felt that it would 
be beneficial in patients with very poor prognosis.64,65
Phase III studies
Two phase III trials have completed accrual, one in combi-
nation with gp100 vaccine, the other a comparison study of 
combination therapy of ipilimumab and dacarbazine with 
dacarbazine and placebo in patients with advanced, stage III 
or IV melanoma. Results from these completed studies are 
currently pending.
Long-term survival benefit 
from ipilimumab
Long-term survival benefit from ipilimumab in patients 
with advanced melanoma has been updated by O’Day 
and colleagues in the 2009 ASCO Annual Meeting.66 Data 
from three studies were updated. These include Study 
CA184-008, a single-arm study of ipilimumab 10 mg/kg, 
Study CA184-022, a randomized dose-ranging study of ipili-
mumab 0.3, 3 or 10 mg/kg, and Study CA184-007, a random-
ized placebo-controlled study of the effect of budesonide on 
gastrointestinal immune-related adverse events in patients 
receiving 10 mg/kg.
In these studies, ipilimuamb was given every 3 weeks × 4 
(induction); eligible patients could continue to receive main-
tenance ipilimumab every 12 weeks from week 24 in all 
studies. Median follow up was from 10.1 to 16.3 months, 
with a range reaching up to 37.5 months. The 12-month 
survival rates were 47%, the 18-month survival rates 
were 34% and the 24-month survival rates were 30%. For 
previously treated patients, 24 month survival rates ranged 
from 24% to 33%. In all three studies, a meaningful propor-
tion of patients continued to survive beyond the updated 
follow-up period. Long-term survivors included patients with 
progressive disease according to the modified World Health 
Organization criteria.
The corresponding median survival times (months) are 
summarized in Table 1.OncoTargets and Therapy 2010:3 21
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Safety and tolerability of single-agent 
ipilimumab
Drug-related AEs were reported in studies with ipilimumab 
as monotherapy as well as in combination studies with 
vaccines, cytokines or chemotherapy. The AE profile of 
ipilimumab is relatively well characterized, with most drug-
related AEs being immune-related adverse events (IRAEs), 
which are considered to be associated with the mechanism 
of action of ipilimumab. The most common IRAEs are 
colitis and diarrhea, rash, pruritis, deficiencies of endocrine 
organs (pituitary, adrenal or thyroid), hepatitis, and uveitis. 
Rare complications are bowel perforations (∼1%) resulting 
from underlying severe colitis, which have required surgical 
intervention. An association was noted between tumor regres-
sion and the development of IRAEs in patients with either 
renal cell carcinoma or metastatic melanoma. It was also 
seen that patients with resected high-risk melanoma expe-
rienced an extended period of time to relapse, regardless of 
concomitant administration of a peptide vaccine.67 Though 
the clinical benefit can still be seen in patients that did not 
develop IRAEs.68
Studies have shown that the administration of steroids 
did not affect the overall antitumor activity of ipilimumab, 
though it was seen that administration of a prophylactic 
corticosteroid, budesonide, did not impart any clinical 
benefit.49,69,70
Discussion: overview of anti-CTLA4 
monoclonal antibodies
Increasing understanding of CTLA-4 and its role as a key 
negative regulator for T-cells has prompted efforts to target 
this signaling molecule as an immunotherapeutic approach. 
Ipilimumab and tremelimumab inhibit CTLA4, prolong-
ing anti-tumor immune responses and leading to durable 
anti-tumor effects. Treatment with these mAbs has dem-
onstrated clinically important and durable tumor responses 
and disease control rates in patients with unresectable 
advanced melanoma. Durable objective responses have been 
reported across a spectrum of doses and schedules, with 
relative safety in this patient population. A recent meta-
analysis of previously collected data from 42 melanoma 
phase II trials conducted by Southwestern Oncology Group 
(SWOG), Eastern Cooperative Oncology Group (ECOG), 
Cancer and Leukemia Group B (CALGB), North Central 
Cancer Treatment Group (NCCTG), and National Cancer 
Institute of Canada Clinical Trials Group (NCIC-CTG) in 
the years 1975 to 2005, reported that 1-year OS or 6-month 
PFS rates should be utilized as benchmarks for future phase 
2 studies. For the 2100 patients included in the analysis, 73 
patients had censored observations for OS (either lost to 
follow-up or still alive at the time of this data collection), 
25 patients of whom had censored observations before 
365 days. The median survival time was 6.2 months (95% 
confidence interval [CI] 5.9 months to 6.5 months), with 
25.5% (95% CI 23.6% to 27.4%) alive at 1 year.71,72 Current 
data from trials with both ipilimumab and tremelimumab 
compare favorably with these rates. Although, the phase III 
tremelimumab melanoma study was closed for “futility”, 
the 1-year survival rate of 50% for tremelimumab and the 
median survival of 11.7 months (compared with 10.7 months 
for chemotherapy) are notable, although this may have 
been the result of the selection criteria for this study. The 
exclusion of patients with 2 × upper limit of normal LDH 
blood values and crossover of patients in the control arm to 
another anti-CTLA4 mAb may also have played a role in 
the results, but this remains to be clarified, and more mature 
survival and response data are anticipated. Results of the 
phase III studies testing CTLA4-blockade with ipilimumab 
(as a single agent or in combination with dacarbazine in one 
study and involving ipilimumab administered in conjunction 
with the gp100 peptide vaccine in another study) are eagerly 
anticipated as well.
Toxicity associated with these agents has not been 
excessive, and we believe that with the experience built 
over the past few years with this new class of agents and 
Table 1 Previous ipilimumab trials
Study (Number of patients) Median survival time (Months)
CA184-008 (N = 155) 10.2, 95% CI (7.6–16.3)
CA184-002 (N = 217) 11.4, 95% CI (6.9–16.1)
with 214 treated;  
n = 72 at 10 mg/kg
Ipilimumab + placebo  
(n = 57)
19.3, 95% CI (12.0–Not reached)
CA184-007 
(N = 115)
Ipilimumab + budesonide  
(n = 58)
17.7, 95% CI  (6.8–Not reached) OncoTargets and Therapy 2010:3 22
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the management of treatment related toxicities it would be 
possible to demonstrate a better safety profile than has been 
shown in the earlier studies. The most commonly reported 
adverse events are colitis, diarrhea, pruritis, dermatitis, 
and fatigue.1,11,73 Adverse events associated with CTLA4 
blockade are generally less severe than with high dose IL-2 
or high dose IFN-α. Initial clinical trials have indicated that 
anti-CTLA4 mAbs cause acute immune activation, as 
evidenced by an increase in CD8+ CTL infiltrates in the 
tumor, and may produce transient autoimmune manifesta-
tions (eg, colitis/diarrhea and dermatitis) that may be severe 
requiring corticosteroid therapy but that generally resolve 
with no long-term sequelae. Long-term treatment with anti-
CTLA4 mAbs may potentially result in chronic autoimmune 
phenomena similar to IFN-α and IL-2 (eg, vitiligo and endo-
crine abnormalities), but there are limited data on long-term 
treatment. Notably, the treatment of autoimmune phenomena 
with systemic corticosteroids has not to date compromised 
the clinical benefit of CTLA4 blockade.74 Based on the results 
of early clinical trials, adjuvant trials are being planned with 
CTLA4 blockade.
The future of CTLA-4 blocking antibodies will include 
testing in the neoadjuvant melanoma setting (ipilimumab). 
This study will be initiated in the autumn of 2009. Neoad-
juvant therapy allows new insights into melanoma and its 
biological and immunologic response to therapeutic interven-
tions, such as ipilimumab. Neoadjuvant ipilimumab therapy 
for high-risk melanoma patients with bulky regional stage 
IIIB-C lymphadenopathy may result in improved clinical 
outcome in this group of patients that are more likely to 
respond to immunotherapeutic interventions and without 
increased morbidity. Through the design of neoadjuvant trials 
in which it is possible to obtain biopsy samples, a greater 
understanding of the dynamic interaction between tumors 
and the immune system is possible. This should lead to the 
identification of new targets for the treatment of melanoma 
and aid in the development of new combinations that may 
have greater efficacy and acceptable toxicity, to build on the 
clinical, immunologic, and molecular effect of this therapy 
for patients with melanoma.
The further development of these agents also includes 
testing in the adjuvant high risk melanoma setting. EORTC 
18071 is an ongoing phase III international trial for 
patients with resected stage III melanoma (IIIA with metas-
tasis 1 mm, any IIIB, IIIC except in-transit metastases). 
Patients will be randomized for treatment with either ipili-
mumab or placebo (induction: 10 mg/kg, 4 × every 21 days. 
maintenance: starting from Week 24, every 12 weeks until 
week 156 or progression, maximum 3 years). A second 
adjuvant trial (E1609) currently in the planning is propos-
ing to test 1-year regimens of ipilimumab versus high-dose 
IFN-α2b. Through the systematic prospective banking of 
initial biopsy blocks (at baseline), serum and PBMC at base-
line and multiple time-points during and following therapy, 
E1609 will allow the performance of novel biomarker evalu-
ations, comparing HDI, and anti-CTLA4 blockade. Based 
on immunologic and immunogenetic markers selected, 
models could be developed to predict responsiveness to 
ipilimumab and to IFN-α2b. In addition, it may provide the 
rationale for assessment of these markers in other stages of 
melanoma, and with other immunotherapeutic modalities, 
including IL-2.
Rationale for the testing of CTLA-4 blocking antibodies 
in the earlier adjuvant and neoadjuvant settings also comes 
from the fact that the quality of the host immune response 
has been shown to differ between patients with earlier micro-
metastatic and more advanced measurable disease settings. 
While T helper type 1 (Th1)-type CD4+ antitumor T-cell 
function appears critical to the induction and maintenance of 
antitumor cytotoxic T lymphocyte (CTL) responses in vivo, 
Th2- or Th3/Tr-type CD4+ T-cell responses may subvert 
Th1-type cell mediated immunity providing a microenvi-
ronment conducive to disease progression. Patients with 
active melanoma or renal cell carcinoma have been shown to 
display strong tumor antigen-specific Th2-type polarization. 
By contrast, normal donors and patients who are disease 
free following therapy demonstrate either mixed Th1/Th2 
type or strongly polarized Th1-type responses to the same 
epitopes.75,76 Therefore, factors of host immune tolerance 
appear to impede advanced disease therapy, and these may 
be less pronounced in the high-risk operable setting, in 
which the host may be more susceptible to immunological 
interventions. This observation is supported by the clinical 
experience with HDI, which reduces relapse risk by up to 
33% in the adjuvant setting, but induces response in only 
16% of patients with advanced disease.
Future progress with CTLA-4 blockade therapy will likely 
come from the use of combinations of agents that modulate 
immune response in the host is a synergistic fashion. Support 
for this strategy comes from testing in preclinical models 
where monotherapy with anti-CTLA-4 was not effective 
in rejecting the highly tumorigenic, poorly immunogenic 
murine melanoma B16-BL6.77 On the other hand, combi-
nation with a granulocyte/macrophage colony-stimulating 
factor (GM-CSF)-expressing tumor cell vaccine was found 
to be therapeutically effective. This combination strategy OncoTargets and Therapy 2010:3 23
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with GM-CSF will be tested in the E1608 trial to be started 
in the autumn of 2009.
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